PT  - JOURNAL ARTICLE
AU  - Qiao, Na
AU  - Reynaud, Denis
AU  - Demin, Peter
AU  - Halushka, Perry V.
AU  - Pace-Asciak, Cecil R.
TI  - The Thromboxane Receptor Antagonist PBT-3, a Hepoxilin Stable Analog, Selectively Antagonizes the TPα Isoform in Transfected COS-7 Cells
AID  - 10.1124/jpet.103.056705
DP  - 2003 Dec 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 1142--1147
VI  - 307
IP  - 3
4099  - http://jpet.aspetjournals.org/content/307/3/1142.short
4100  - http://jpet.aspetjournals.org/content/307/3/1142.full
SO  - J Pharmacol Exp Ther2003 Dec 01; 307
AB  - The hepoxilin analog PBT-3 [10(S)-hydroxy-11,12-cyclopropyleicosa-5Z,8Z,14Z-trienoic acid methyl ester] was previously shown to inhibit the aggregation of human platelets and to antagonize the binding of the thromboxane receptor agonist I-BOP [[1S-[1α,2α (Z),3β(1E,3S*),4α]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid] in human platelets (Pace-Asciak et al., 2002). We show herein that PBT-3 inhibits, to different degrees, binding of the TP receptor antagonist [3H]SQ 29,548 [[1S-[1α,2α (Z),3α,4α]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2. 1]hept-2-yl]-5-heptenoic acid], to the TP receptor isoforms in TPα- and TPβ-transfected COS-7 cells. These isoforms possess a different tail length, the α being shorter than the β isoform. In contrast, SQ 29,548 shows no selection for the two TP isoforms. The IC50 value for PBT-3 = 2.0 ± 0.3 × 10–7 M was observed for TPα, whereas this was one-sixth less active on the TPβ isoform (IC50 = 1.2 ± 0.2 × 10–6 M), suggesting selectivity for the TPα isoform. To investigate whether the tail contributes to the difference in competition binding by PBT-3, we investigated the tailless TP isoform expressed in transfected COS-7 cells. Its IC50 was similar to that of the TPα isoform. In additional studies, we investigated the effect of PBT-3 on the collagen and I-BOP evoked intracellular calcium release and on the collagen and I-BOP evoked phosphorylation of pleckstrin. PBT-3 blocked both pathways further demonstrating its TP receptor antagonist activity. These results demonstrate that the action of PBT-3 in inhibiting platelet aggregation is mediated via inhibition of the TPα isoform of the thromboxane receptor and that the tail may play an important role in recognition of this TP receptor antagonist. The American Society for Pharmacology and Experimental Therapeutics